Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
Tasly Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the first half of 2025, showing a slight decline in revenue by 1.91% compared to the same period in 2024. Despite the revenue drop, the net profit attributable to shareholders increased by 16.97%, indicating improved profitability. However, the net profit after extraordinary gains or losses decreased by 12.87%, and the net cash flow from operating activities fell by 10.95%. The company’s total assets and net assets attributable to shareholders saw modest increases of 3.15% and 3.98%, respectively, reflecting a stable financial position.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company holds a significant equity interest in Tasly Pharmaceutical, which is listed on the Shanghai Stock Exchange.
Average Trading Volume: 11,247,567
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.05B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money